iRhythm Technologies, Inc. (IRTC) Stock

Understand iRhythm Technologies, Inc.: how it makes money

iRhythm Technologies provides ambulatory ECG monitoring using its Zio service, combining a wire-free, patch-based wearable (single-use monitors) with a cloud-based data analytics platform that physicians use to monitor patients and diagnose arrhythmias, driving revenue through Zio-related monitoring services and associated monitor use in the United States.

The Zio offering links single-use, wire-free patch ECG monitors to ongoing (long-term continuous) monitoring, with cloud analytics and high patient wear time helping sustain repeat monitoring volume, which is reflected in the Long-Term Continuous Monitoring Segment Share.

Business quality (Weak): Strong gross margin (70.9%), but operating loss in the latest quarter (operating margin -8.1%), suggesting meaningful costs to scale beyond current revenue levels.

Bull case

• Long-term monitoring is a large part of the mix: Long-Term Continuous Monitoring Segment Share is 72.0%, which aligns with a business model aimed at recurring monitoring rather than one-time tests.
• Operational execution supports usable ECG data capture: Patient Patch Wear Time Adherence Up to Fourteen Days is 98.0%, helping ensure the monitoring is completed as prescribed, which is important for downstream interpretation.
• Newest generation adoption is underway: Long-Term Continuous Monitoring Registrations Using Newest-Generation Ambulatory Cardiac Monitor is 67.0%, indicating continued shift toward newer devices within the long-term monitoring population.

Bear case

• Profitability is not yet positive: The latest quarter shows an operating margin of -8.1%, meaning operating costs exceeded operating revenue during the period.
• The model depends on maintaining long-term monitoring engagement: With Long-Term Continuous Monitoring representing 72.0% of the mix, any decline in that share or in long-term registrations could pressure utilization of the Zio service.
• Clinical and workflow performance must remain high: Key performance depends on high adherence and accurate clinically relevant arrhythmia detection (for example, Pre-Identification Accuracy is 85.0% and wear time adherence is 98.0%), and any deterioration could reduce monitoring usefulness and physician confidence.

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• Teleflex Incorporated (TFX)
• MiniMed Group, Inc. (MMED)
• Merit Medical Systems, Inc. (MMSI)
• Haemonetics Corporation (HAE)
• ICU Medical, Inc. (ICUI)
• Heartflow, Inc. Common Stock (HTFL)
• Pulse Biosciences, Inc. (PLSE)
• UFP Technologies, Inc. (UFPT)